| 2025 |
Mekonnen, L. B., Teo, T., Noll, B., Rahaman, M. H., Lenjisa, J., Basnet, S., . . . Wang, S. (2025). A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189(118340), 118340.
DOI Europe PMC1 |
| 2023 |
Mustafa, E. H., Laven-Law, G., Kikhtyak, Z., Nguyen, V., Ali, S., Pace, A. A., . . . Hickey, T. E. (2023). Selective inhibition of CDK9 in triple negative breast cancer. Oncogene, 43(3), 202-215.
DOI Scopus13 WoS13 Europe PMC9 |
| 2023 |
Islam, S., Rahaman, M. H., Yu, M., Noll, B., Martin, J. H., Wang, S., & Head, R. (2023). Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition. Cancers, 15(4), 21 pages.
DOI Scopus5 WoS4 Europe PMC5 |
| 2022 |
Anshabo, A. T., Bantie, L., Diab, S., Lenjisa, J., Kebede, A., Long, Y., . . . Wang, S. (2022). An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers, 14(5), 1113.
DOI Scopus12 WoS10 Europe PMC10 |
| 2021 |
Yu, M., Long, Y., Yang, Y., Li, M., Teo, T., Noll, B., . . . Wang, S. (2021). Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation. European Journal of Medicinal Chemistry, 218(113391), 23 pages.
DOI Scopus9 WoS8 Europe PMC8 |
| 2021 |
Yu, M., Teo, T., Yang, Y., Li, M., Long, Y., Philip, S., . . . Wang, S. (2021). Potent and orally bioavailable CDK8 inhibitors: design, synthesis, structure-activity relationship analysis and biological evaluation. European Journal of Medicinal Chemistry, 214, 1-22.
DOI Scopus14 WoS13 Europe PMC11 |
| 2021 |
Sallustio, B. C., Noll, B. D., Hu, R., Barratt, D. T., Tuke, S. J., Coller, J. K., . . . Somogyi, A. A. (2021). Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 87(10), 3901-3909.
DOI Scopus21 WoS21 Europe PMC14 |
| 2020 |
Bantie, L., Tadesse, S., Likisa, J., Yu, M., Noll, B., Heinemann, G., . . . Wang, S. (2020). A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.. Gynecol Oncol, 159(3), 827-838.
DOI Scopus16 WoS18 Europe PMC16 |
| 2019 |
Rahaman, M. H., Yu, Y., Zhong, L., Adams, J., Lam, F., Li, P., . . . Wang, S. (2019). CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Investigational new drugs, 37(4), 625-635.
DOI Scopus34 WoS33 Europe PMC27 |
| 2019 |
Abdelaziz, A. M., Diab, S., Islam, S., KC Basnet, S., Noll, B., Li, P., . . . Wang, S. (2019). Discovery of n-phenyl-4-(1h-pyrrol-3-yl)pyrimidin-2-amine derivatives as potent mnk2 inhibitors: design, synthesis, sar analysis, and evaluation of in vitro anti-leukaemic activity. Medicinal chemistry, 15(6), 600-621.
DOI Scopus6 WoS5 Europe PMC5 |
| 2019 |
Sallustio, B. C., Noll, B. D., Coller, J. K., Tuke, J., Russ, G., & Somogyi, A. A. (2019). Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation. British Journal of Clinical Pharmacology, 85(5), 1015-1020.
DOI Scopus5 WoS3 Europe PMC4 |
| 2019 |
Lee, K. J., Tieu, W., Blanco-Rodriguez, B., Paparella, A. S., Yu, J., Hayes, A., . . . Abell, A. D. (2019). Sulfonamide-based inhibitors of biotin protein ligase as new antibiotic leads. ACS Chemical Biology, 14(9), 1990-1997.
DOI Scopus9 WoS8 Europe PMC5 |
| 2018 |
Tadesse, S., Bantie, L., Tomusange, K., Yu, M., Islam, S., Bykovska, N., . . . Wang, S. (2018). Discovery and pharmacological characterisation of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents. British journal of pharmacology, 175(12), 2399-2413.
DOI Scopus23 WoS22 Europe PMC18 |
| 2018 |
Sweetman, M. J., Sebben, D., Noll, B. D., Wang, W. H., May, S., Mebberson, N., . . . Hayball, J. D. (2018). A rapid technique to determine performance and efficiency of activated carbon water filters. Water science and technology: water supply, 18(2), 371-382.
DOI Scopus10 WoS9 |
| 2017 |
Tadesse, S., Yu, M., Mekonnen, L. B., Lam, F., Islam, S., Tomusange, K., . . . Wang, S. (2017). Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation. Journal of medicinal chemistry, 60(5), 1892-1915.
DOI Scopus72 WoS65 Europe PMC40 |
| 2017 |
Diab, S., Abdelaziz, A. M., Li, P., Teo, T., Basnet, S. K. C., Noll, B., . . . Wang, S. (2017). Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. European journal of medicinal chemistry, 139, 762-772.
DOI Scopus23 WoS22 Europe PMC19 |
| 2017 |
O'Brien Brown, J., Jackson, A., Reekie, T. A., Barron, M. L., Werry, E. L., Schiavini, P., . . . Kassiou, M. (2017). Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists. European journal of medicinal chemistry, 130, 433-439.
DOI Europe PMC22 |
| 2016 |
Sutton, S. K., Carter, D. R., Kim, P., Tan, O., Arndt, G. M., Zhang, X. D., . . . Marshall, G. M. (2016). A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. Oncotarget, 7(32), 52166-52178.
DOI Scopus10 Europe PMC9 |
| 2015 |
Li, K. L., Bray, S. C., Iarossi, D., Adams, J., Zhong, L., Noll, B., . . . D'Andrea, R. J. (2015). Investigation of a novel cyclin-dependent-kinase (CDK) inhibitor Cdki-73 as an effective treatment option for MLL-AML. Blood, 126(23), 1365.
DOI WoS5 |
